In addition, the benefits of combination therapy with disulfiram can also be applied to other drugs, such as pazopanib and axitinib, because these drugs are also clinically used to block tumor angiogenesis through VEGFR inhibition, similar to sunitinib for the treatment of RCC. Here, KDR is linked to neoplasm.